A case of new‐onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma. Issue 12 (17th October 2016)

• Record Type: Journal Article
• Authors: Wallace, Natalie; Wong, Ellice; Cooper, Dennis; Chao, Herta
• Is Part Of: Clinical case reports. Volume 4:Issue 12(2016)
• Page Start: 1120
• Page End: 1121
• Publication Date: 2016-10-17
• Subjects: Arrhythmia -- cardiomyopathy -- ibrutinib -- mantle cell lymphoma -- tyrosine kinase inhibitor; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.719
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: Ibrutinib is a first‐in‐class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia. Abstract : Ibrutinib is a first‐in‐class inhibitor of Bruton's tyrosine kinase, which is approved for use in chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although ibrutinib has been linked to an increased incidence of atrial fibrillation, this is the first report of an association with nonischemic cardiomyopathy and ventricular arrhythmia.